Latest Tax Incentives News

Energy Action Limited reports a strong positive operating cash flow of $1.08 million in Q2 FY25, boosted by customer receipts and an R&D tax rebate, while advancing its AI-driven energy platform Utilibox to fuel future growth.

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Algorae Pharmaceuticals reports robust progress in its drug development pipeline, highlighted by promising preclinical results for cardiovascular and dementia candidates and significant AI platform enhancements.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.

Aruma Resources advances its exploration portfolio with standout assay results at Fiery Creek and strategic leadership changes, setting the stage for upcoming drilling campaigns.

Syntara Limited reported a robust $11.35 million increase in cash during the December 2024 quarter, underpinned by government grants and steady operational inflows. The company closes the period with a strong cash position of $18.07 million, signaling financial resilience.

4DMedical reports a remarkable 202% increase in Q2 FY2025 operating revenue, driven by rapid site expansion and key collaborations with leading healthcare providers and the U.S. Department of Defense.

Livium Ltd reports a 179% surge in recycling gross profit and advances its lithium extraction technology, positioning itself strongly in the evolving battery materials market.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.

Mighty Kingdom Ltd has received $1.809 million in tax rebates, significantly enhancing its capital flexibility as it refines operations and explores future growth opportunities.